Although people have greater access to personalized drugs and tests than ever before, a survey by GenomeWeb and the PMC shows public awareness isn't improving.  

The centers will generate genotype and whole-genome sequence data from the samples submitted by participants.

The companies plan to develop a pan-cancer CDx to measure microsatellite instability and CDx tests for tumor mutational burden and other novel biomarkers of response.

The financing round will support Grail's ongoing development and validation of early cancer detection products.

While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.

The company plans to test both its current technology and explore novel signatures using samples from Mayo's biobank.

The funding will be available to members of the Association of Community Cancer Centers, a cancer care provider advocacy group.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

May
08
Sponsored by
Applied Spectral Imaging

The introduction of digital pathology has opened the door to countless new possibilities. Whole Slide
Imaging, computational image analysis and automated workflows are redefining pathology and shaping
the future of cancer care. Join us as we review new applications in digital pathology which provide the
necessary tools pathologists need in order to meet the growing demands of modern pathology.

The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.

As the field of therapeutic antibody research expands, scientists face a growing need for software that enables them to efficiently and accurately analyze their data. Highly functional bioinformatics software solutions significantly reduce the need to manually curate sequence data or convert it into different formats for sharing and archiving. Unfortunately, there are currently few specialist antibody screening and analysis platforms that can be quickly configured to meet the highly custom needs of specialized therapeutic antibody discovery organizations.